Shares of French biotech firm Abivax soared Tuesday after it launched recent information on its lead drug for bowel illness, clawing again heavy losses from earlier within the month when the identical trial had traders questioning the drug’s future.
Abivax inventory was final buying and selling up 29.9%. The transfer comes after it crashed round 44% on June 2, following an information set that confirmed there have been most cancers instances amongst sufferers taking the very best dose of its experimental medication obefazimod for ulcerative colitis (UC).
Extra information on the late-stage scientific trial, launched late on Monday, confirmed that malignancies had been in keeping with ranges usually seen in UC sufferers. The corporate additionally mentioned that over 37% of sufferers who did not reply to therapy initially, then achieved scientific remission after therapy with a 50 mg dose, after about 10 months.
“These findings recommend {that a} significant proportion of sufferers who don’t initially reply should derive substantial profit from longer therapy publicity,” Abivax mentioned.
The trial was a so-called upkeep research that examined remission charges amongst sufferers with ulcerative colitis over 44 weeks. The Monday replace was the second, supplemental a part of the Section 3 trial.
Jefferies analysts known as the replace “supportive,” however mentioned they questioned whether or not this might be sufficient for traders given “most cancers danger could also be robust to low cost, sparse catalyst path, money wants, catalyst path ex-M&A.”
Abivax has been positioned as a first-rate takeover goal, with unverified rumors that a number of Huge Pharma corporations have their eye set on buying the Paris-based clinical-stage biotech. Shares gained almost 1,700% in 2025 however had fallen 14% year-to date coming into Tuesday buying and selling.
The inventory has but to recuperate absolutely from the drop earlier this month when it traded above 111 euros ($127) a share.
Abivax shares over the previous yr.
The Jefferies analysts mentioned that specialist traders and physicians had been prone to put the malignancy situation behind them, however that generalist traders may nonetheless be hesitant to personal the inventory.
Earlier this month, Abivax reported that there have been seven instances of various cancers within the research cohort, which had been all thought-about not or unlikely to be associated to therapy.
“The expanded cumulative security information additional strengthens our confidence within the long-term security profile of obefazimod and reinforces the favorable benefit-risk profile for our program as we put together for our deliberate [new drug application] submission later this yr,” CEO Marc de Garidel mentioned in an announcement on Monday.
Abivax mentioned it stays on monitor to submit its NDA to the U.S. Meals and Drug Administration for obefazimod within the fourth quarter of 2026. It has beforehand mentioned {that a} launch is probably going in 2027, however it’s broadly thought-about that the corporate will probably be acquired earlier than then.
Analysts have described the experimental drug as a possible best-in-class therapy for ulcerative colitis. Abivax can be testing the drugs for Crohn’s illness, opening it as much as a multi-billion-dollar marketplace for Inflammatory Bowel Illness (IBD).
A trial evaluating the drug in sufferers with Crohn’s illness is anticipated in mid-2027.
